![]() The brokerage firm has maintained ‘buy’ rating on Sun Pharma with a target price of Rs 860 per share as the drug maker is making steady progress in its differentiated pipeline, particularly in the derma and opthal space. CLSA has cited Sun Pharmaceutical Industries, Lupin, Dr Reddy’s and Torrent Pharmaceuticals as its best ideas. But at the same time, the importance of India and emerging markets should increase for the drug makers due to the strong growth outlook, brokerage CLSA has said in a note.Īccording to the brokerage, large-cap drugmakers are better positioned to ride the next wave of growth in the US owing to their superior research and development, better execution, and stronger balance sheets. With rapid price deterioration in the simple generics industry in the US, Indian pharma companies are in a challenging situation. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |